SOURCE: SpeechSwitch, Inc.

June 21, 2010 10:00 ET

SpeechSwitch, Inc. (PINKSHEETS: SSWC) Preliminary Report on Healthcare Division

FLEMINGTON, NJ--(Marketwire - June 21, 2010) - Ken Glynn, President of SpeechSwitch, Inc. (PINKSHEETS: SSWC), reported today on the status of its Healthcare Division:

(1) In June 2009 the company obtained all rights to the GlynnTech, Inc. cancer drug delivery system, at cost. This includes one issued patent (US No. 7,637,889 B2), one pending application, three years of development work, a prototype, numerous CAD drawings of various embodiments, risk analysis and development pre-FDA filing history. Ken had three meetings with a major pharma company who expressed serious interest and has indicated that a contract will likely be offered for acquisition of the intellectual property after FDA filings have been made, but before FDA approval. If successful, a seven figure payment would be expected.

(2) In February 2010, the company acquired a pending patent application on one of Ken's inventions in the healthcare field, specifically, a cell phone with dual temperature reading and heart monitoring capabilities. The dual temp feature may be used to measure room temperature or outdoor temperature in a first mode, and to measure body temperature to determine presence of a fever in a second mode. The heart monitoring feature includes low, high and irregular heartbeat detection and warning signals (optionally to a wireless remote receiver, such as a doctor or other care center).

(3) Recently, Ken came up with novel methods for inhibiting bacterial release of toxins. Preliminary patent and literature searches are being conducted at this time. If the results are favorable, as initial results indicate, this will be the core of the first SSWC-filed patent application since Ken took over.

(4) Other healthcare developments are embryonic and will be reported at future dates. Because this Division is not producing products, but is dedicated to licensing and/or selling patent rights, profit margins are expected to be atypically large. 

Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," 'should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. 

Contact Information

  • Contact:
    Ken Glynn
    908 788 0077